Mystery Solved? GenSight’s Gene Therapy Does Move Between Eyes
Company hopes to file in Europe next year
Executive Summary
Company boosted by animal study which helps answer riddle of improvement in untreated eye.
You may also be interested in...
REFLECT Study Confirms Efficacy Of GenSight's Gene Therapy Lumevoq
French biotech GenSight Biologics reports top-line results from the Phase III REFLECT study, backing the efficacy of its lead gene therapy in a devastating eye disease, and prepares plans to commercialize the product.
GenSight Undeterred By Gene Therapy’s Placebo Puzzle
Phase III success at 96 weeks sets up GenSight blindness therapy for EU filing, but puzzle of placebo arm benefits remain
Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence
The company hopes for a “Humira-like” blockbuster with povetacicept, the object of the sector’s biggest M&A deal so far this year.